**Name of Journal:** *World Journal of Gastrointestinal Pharmacology and Therapeutics*

**ESPS Manuscript NO: 21266**

**Manuscript Type: Review**

**Clinical applications, limitations and future role of transient elastography in the management of liver disease**

Chang PE *et al.* Clinical applications of transient elastography

**Pik Eu Chang, George Boon-Bee Goh, Jing Hieng Ngu, Hiang Keat Tan, Chee Kiat Tan**

**Pik Eu Chang, George Boon-Bee Goh, Jing Hieng Ngu, Hiang Keat Tan, Chee Kiat Tan,**Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 169586, Singapore

**Pik Eu Chang, Chee Kiat Tan,** Duke-NUS Graduate Medical School, Singapore 169587, Singapore

**Author contributions:** Chang PE designed the framework of the review, performed the final edits and revision of the manuscript; Chang PE, Goh GBB, Ngu JH, Tan HK and Tan CK contributed towards drafting the article and final approval of the manuscript.

**Conflict-of-interest** **statement:** None of the authors have any conflict of interests related to this study.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Dr. Pik Eu Chang, Jason,** Department of Gastroenterology and Hepatology, Singapore General Hospital, 20 College Road, Level 3, Academia Building, Singapore 169856, Singapore. jason.chang@sgh.com.sg

**Telephone:** +65-63214684

**Fax:** +65-62273623

**Received:** July 2, 2015

**Peer-review started:** July 9, 2015

**First decision:** August 25, 2015

**Revised:** September 22, 2015

**Accepted:** October 23, 2015

**Article in press:**

**Published online:**

**Abstract**

Transient elastography (TE) is a reliable tool for the non-invasive assessment of liver fibrosis in routine clinical practice. TE is currently approved for use in Europe, Asia and the United States. The widespread adoption of this technology is certain to increase the use of TE worldwide. Although TE has been well validated in chronic viral hepatitis, its clinical role in other liver diseases remains less clear. The advent of new treatment for chronic hepatitis C and emerging prevalence of non-alcoholic steatohepatitis raises new questions on the role of TE in current clinical practice. This review aims to examine the clinical applications, limitations and future role of TE in current clinical practice in light of the changing epidemiology of liver diseases and new clinical management paradigms. In current clinical practice, TE is the most accurate non-invasive method for diagnosis of liver cirrhosis. TE is useful to rule out fibrosis and cirrhosis but does not have sufficient accuracy to discern between various stages of fibrosis. The clinical role of TE has evolved from cross-sectional point-in-time assessment of fibrosis and cirrhosis to the more relevant role of prediction of vital clinical end-points. This provides clinicians with the ability to modify treatment strategies based on the information provided by TE. TE has evolved over the past decade to become an essential tool to assist the clinician in the management of chronic liver disease.

**Key words**: Liver stiffness; Transient elastography; Non-invasive; Fibrosis; Chronic

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Transient elastography (TE) is a reliable tool for the non-invasive assessment of liver fibrosis in routine clinical practice. Although TE has been well validated in chronic viral hepatitis, its clinical role in other liver diseases remains less clear. The advent of new treatment for chronic hepatitis C and emerging prevalence of non-alcoholic steatohepatitis raises new questions on the role of TE in current clinical practice. This review aims to examine the clinical applications, limitations and future role of TE in current clinical practice in light of the changing epidemiology of liver diseases and new clinical management paradigms.

Chang PE, Goh GBB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. *World J Gastrointest Pharmacol Ther* 2015; In press

**INTRODUCTION**

Liver fibrosis is the common end-point of a variety of chronic liver diseases. The progression of liver fibrosis leads to cirrhosis, decompensation, liver failure, hepatocellular carcinoma (HCC) and death[1]. Accurate diagnosis of liver fibrosis and cirrhosis is essential for prognostication of liver disease and for timely intervention to prevent negative outcome. Liver biopsy was the traditional gold standard for diagnosis of fibrosis, but significant progress has been made in the field of non-invasive assessment of liver fibrosis over the past decade such that the role of liver biopsy has been diminishing in clinical practice. Non-invasive markers of fibrosis include serum markers which assess the biochemical properties of fibrosis and elastography devices which assess the physical stiffness of the fibrotic liver. Transient elastography (TE) measured by Fibroscan® (Echosens, France) was the first of such elastography devices, followed by magnetic resonance elastography (MRE), acoustic radiation force impulse (ARFI) and shear wave elastography (SWE). In current clinical practice, TE is the most widely used elastography device for non-invasive assessment of liver fibrosis and is popular in Europe, Asia and recently North America as well.

TE works by measuring shear wave speed through the liver[2]. A handheld probe is placed in the intercostal space of the patient over the right lobe of the liver[3]. A vibration pulse of mild amplitude and low frequency is transmitted by the transducer. This induces a shear wave that propagates through the liver. Pulse-echo ultrasonic acquisitions are simultaneously performed by the machine to follow the shear wave and to measure its velocity. The velocity of the returning shear waves is measured at a depth of 25-65 mm when using the standard M probe and 35-75 mm with the XL probe. This provides an indication of the stiffness of the liver, which is expressed in kPa. The stiffer the liver, the faster the shear wave and hence the higher the liver stiffness measurement (LSM) value. At least 10 successful measurements are required for a valid assessment. The TE result is reported as the median value of at least 10 successful LSMs.

**LIMITATIONS OF TE**

Before we review the use of TE in clinical practice, it is important to be familiar with the limitations of this new technology. Although TE has been proposed as a non-invasive tool to measure liver fibrosis, TE actually measures the the shear wave speed through the liver which reflects liver stiffness and not actual amount of fibrosis in the liver. Hence, conditions which increase the stiffness of the liver independent of fibrosis will result in an increased LSM and will result in a falsely high estimate of liver fibrosis.

*Acute hepatitis*

TE has been demonstrated to be unreliable in acute hepatitis, with LSM values increasing 1.3 to 3 fold during alanine transaminase (ALT) flares[4,5]. This can lead to inaccurate diagnosis of cirrhosis in patients with acute transaminitis. A clear correlation between aminotransferases and LSM has been described, with LSM values falling to normal range after resolution of the acute liver injury[6]. It is thus advised that TE be avoided in situations where there is acute hepatitis as the LSM result is likely to overestimate the degree of fibrosis. The LSM should be repeated when or delayed till recovery from the acute liver injury when the ALT levels return to the baseline. It has been suggested that caution should be applied in the interpretation of LSM values when the ALT level is above 100 IU/L. This poses a clinical dilemma in conditions where there is constant fluctuation of transaminitis, for example in chronic hepatitis B (CHB). Initial validation studies of LSM were largely performed in patients with chronic hepatitis C (CHC) and did not report any association between LSM and ALT[7]. However studies in patients with CHB reported a significant correlation between ALT and LSM[8]. From a clinical perspective, it is not feasible to discount the LSM in every CHB patient who has an ALT level > 100 IU/L since many CHB patients would be expected to have fluctuations in ALT. This has led to proposals to use different LSM cut-off values and algorithms for fibrosis estimation for patients with normal and elevated ALT[9]. A large multicentre study recently demonstrated that ALT and LSM maintain a weak linear relationship for each fibrosis stage up to an ALT of 300 IU/L and proposed using probability-based interpretation of LSM using the LiFA-HBV score[10]. This new score helps the clinician to assess the probability of severity of fibrosis based on the LSM and ALT. For example, a patient with an LSM of 18.4 kPa and a normal ALT of 35 IU/L would have a 0.97 probability of F2 fibrosis, a 0.89 probability of F3 fibrosis and a 0.73 probability of cirrhosis. Another patient with the same LSM of 18.4 kPa but an elevated ALT of 350 IU/L would have a 0.97 probability of F2 fibrosis, 0.77 probability of F3 fibrosis but only 0.35 probability of cirrhosis. This provides the clinician with a practical and useful way of interpreting LSM in patients with elevated ALT in order to make appropriate clinical decisions. However, the LiFA-HBV score was developed based on untreated CHB patients and requires further validation in other liver diseases.

*Hepatic congestion*

LSM values has been shown to increase significantly after a liquid meal, suggesting that TE should be performed after at least a 3 h fast in order to ensure accuracy of fibrosis assessment[11,12]. Liver stiffness is affected by the central venous pressure[13,14] and has been used as a potential non-invasive measure of decompensated chronic heart failure[15] and in congenital heart disease[16]. It is thus important for clinicians to be aware that TE is not suitable for assessment of liver fibrosis in patients in cardiac failure and those with tricuspid regurgitation as it will lead to an overestimation in the severity of liver fibrosis. This poses a clinical challenge in the assessment of patients with cardiac causes of fibrosis, *e.g.*, those with chronic congestive hepatopathy as a result of Fontan procedure for complex congenital heart disease[17]. TE has been reported to be useful for identifying Fontan patients with significant liver fibrosis and cirrhosis[18,19]. However in the absence of biopsy confirmation, LSM cannot be considered to be a reliable predictor for liver cirrhosis as an elevated liver stiffness value cannot differentiate between hepatic congestion and hepatic fibrosis.

*Cholestasis*

Extrahepatic cholestasis leads to increased liver stiffness values and results in false estimation of severity of fibrosis. Studies in patients with extrahepatic biliary obstruction either due to neoplasm or choledocholithiasis report elevated LSM readings which declined significantly on repeat TE after biliary drainage[20-23]. It has been suggested that TE should be avoided in patients with significant hyperbilirubinemia (bilirubin > 100 ≥ µmol/L) and should be repeated after biliary drainage when the bilirubin levels return to baseline[20,23].

*Operator experience*

TE has been described to be an operator-independent procedure with a high inter-observer agreement of up to 98%[24]. However a large review of 13369 TE examinations over 5 years demonstrated LSM failure in 3.1% and unreliable LSM in 15.8%. Both were associated with two main factors: Elevated body mass index (BMI) > 30 kg/m2 and operator experience of less than 500 examinations[25]. In a separate French study of TE in 935 patients, the odds ratio (OR) for successful LSM were significantly higher for operators with prior experience of 50-99 measurements and even higher with > 100 previous measurements[26]. Poor operator technique may result in a higher variability of LSMs, which is reflected by a higher interquartile range (IQR). LSM measurements with an IQR greater than 30% of the median value (IQR/M > 0.3) are considered to be invalid and should be either repeated or discarded. In a study examining factors affecting accuracy of TE in patients with CHC fibrosis, an IQR/M ≥ 0.21 was associated with an increased likelihood of inaccurate TE assessment, with an OR of 2.23[27]. The authors suggest that TE measurements with IQR/M ≥ 0.21 should be repeated, and if the repeat LSM has a consistent IQR/M ≥ 0.21, the assessment should be discarded and alternative methods to assess liver fibrosis should be explored. One of the most important factors related to operator technique is the maintenance of perpendicularity of the probe to the liver surface. Correct positioning of the probe is also important to achieve reliable LSM readings[28]. The available data suggests that while a minimal experience of 50 prior measurements may be sufficient for an operator to perform TE, the reliability of LSM measurements is increased in experienced operators with > 500 previous examinations[29].

*Obesity*

Early studies in TE using the standard M probe encountered a high rate of TE failure between 5%-22% in obese patients with high BMI (> 30 kg/m2) and increased waist circumference[24,25]. This has been attributed to the interference with the transmission of shear waves and ultrasound waves through the liver parenchyma by thick subcutaneous adipose tissue[30]. However, further studies established that the thoracic fatty belt and not BMI per se was the main determinant of TE failures in obese individuals[31]. Subsequent studies established that the primary factor that was responsible for the failure to obtain a LSM result in obese patients was the distance between the skin and the liver capsule. Patients with a skin-capsule distance (SCD) > 2.6 cm due to increased subcutaneous thoracic fat were more likely to have unsuccessful TE examinations using the M probe[32]. This has led to the development of the XL probe, which differs from the M probe in the following features: a lower ultrasound frequency of 3.5 MHz compared to 5 MHz, a greater transducer focal length of 50 mm *vs* 35 mm, a larger probe tip diameter of 12 mm *vs* 9 mm, higher vibration amplitude of 3 mm *vs* 2 mm and measurement depths of 35-75 mm *vs* 25-65 mm. The XL probe is able to provide a valid TE result in approximately 60% of M probe failures[33]. XL probe failures occur when the SCD is > 3.4 cm, which exceeds the measurement depth of the XL probe. Such patients should undergo alternative assessments for liver fibrosis such as MRE which is not affected by subcutaneous thoracic fat.

*Optimal cut-off levels for diagnosis of fibrosis and cirrhosis in different etiologies of liver disease*

One of the difficulties in using TE in routine clinical practice is the variability of optimal cut-off levels for the diagnosis of fibrosis and cirrhosis in different etiologies of liver disease. In a meta-analysis of 40 studies evaluating the diagnostic accuracy of TE in various chronic liver disease[34], the optimal cut-off LSMs for CHC are 7.6 kPa for significant fibrosis and 15.3 kPa for cirrhosis (Table 1). Cut-off levels in CHB are similar although some studies demonstrate a slightly lower LSM cut-off for cirrhosis in CHB compared to CHC[35,36]. TE has been shown to be useful for detection of fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD), but the reported optimal cut-off levels for diagnosis of cirrhosis vary from 10.3 kPa to 17.5 kPa[37-39]. In alcoholic liver disease and cholestatic liver disease, the optimal cut-off levels for diagnosis of cirrhosis are significantly higher than viral hepatitis or NASH. Given the variability of cut-off LSMs, LSM results should be interpreted by based on the underlying etiology of liver disease. However, this poses challenges when patients have concomitant liver disease, *e.g*., CHC and alcoholic liver disease or CHB and NASH. In such situations, most clinicians intuitively use the lower cut-off value to determine the fibrosis stage. However, there have been no studies to date that specifically address this clinical predicament.

One of the underlying reasons for the variability of cut-off levels is that although TE measures amount of fibrosis tissue in the liver, it does not grade the severity of the fibrosis. The METAVIR classification, which is the fibrosis staging system used in most biopsy-paired TE studies, grades severity of fibrosis based on the pattern of fibrosis distribution (*i.e.*, portal fibrosis *vs* portal-central bridging). In contrast, TE simply measures the stiffness of the liver which reflects overall amount of fibrosis tissue in the liver. TE cannot assess the distribution or pattern of fibrosis. This may in part explain the variability of cut-off levels in different diseases. Another contributing factor is that a majority of biopsy-paired validation studies for TE were performed using the METAVIR scoring system as the comparator. While this is relevant for chronic viral hepatitis since the METAVIR system is accurate for staging severity of portal-based fibrosis, it is less relevant for NASH and alcoholic liver disease where the distribution of fibrosis is not predominantly portal-based but pericellular or perivenular, respectively. In a study of accuracy of LSM for the diagnosis of cirrhosis in 1257 patients with various chronic liver disease, Ganne-Carrie *et al*[40] observed that false-positive LSM results were mainly observed in patients with extensive fibrosis. This could reflect a situation where either the liver biopsy has under-staged cirrhosis due to sampling error or there is extensive fibrosis (reflecting a large amount fibrous tissue) but without the nodular architecture required for a pathological diagnosis of cirrhosis.

Differences in the optimal cut-off values reported in different studies can also result from statistical bias. The identification of a specific cut-off value to diagnose a particular fibrosis grade is dependent on the choice of sensitivity and specificity parameters, which in turn depend on the indication for the test and the prevalence of the condition in the study population. For purposes of screening (*e.g*., diagnosis of fibrosis in NAFLD patients), a lower LSM cut-off level would be more clinically applicable so as not to miss subjects who may require treatment. However, this would reduce the specificity of the test and result in more false-positive tests. In contrast, in clinical situations where accurate identification is important, a LSM cut-off level which provides a high specificity is more relevant than sensitivity. For example, accurate identification of patients with cirrhosis in viral hepatitis is important as these subjects would require antiviral treatment, endoscopic variceal screening and routine surveillance for liver cancer. Some authors have proposed the use of dual cut-off LSMs to rule in or rule out fibrosis and cirrhosis in clinical practice[41].

Cut-off values identified for one population may not be applicable to another which has a different prevalence of disease. For this reason, the performance of TE is more accurate for the identification of more advanced degrees of fibrosis compared to mild fibrosis in biopsy-paired studies because there is an inherent bias to biopsy patients in whom severe fibrosis is clinically more likely. In clinical practice, the use of a specific LSM cut-off value to determine fibrosis stage is less reliable, especially when the LSM value is close to the cut-off value or when there are confounding factors present like necroinflammation, congestion or steatosis. The LSM result should be interpreted in a range or continuum as this provides more reliable clinical interpretation of this non-invasive marker. For example, patients with LSM values ranging from 2.5 to 7 kPa are unlikely to have significant fibrosis, whereas patients with LSM > 13 kPa are likely to have cirrhosis[42]. A patient with LSM of 25 kPa is more likely to have definite cirrhosis as compared to a patient with an LSM of 13.5 kPa. Hence, the use of probability-based interpretation of LSM results promise to be the most useful way to interpret LSM in routine clinical practice[10].

*Reliability criteria*

Initial studies in TE defined reliable results as those with at least 10 validated measurements, a success rate of at least 60% and an IQR/M ratio less than 0.3[7]. These criteria were based on the manufacturer’s recommendations. However, the impact of these unreliable TE measurements on accuracy for diagnosis for fibrosis and cirrhosis was not known. Boursier *et al*[43] evaluated the relevance of the recommended reliability criteria in a large multicentre cohort with the aim of improving reliability by using diagnostic accuracy as the primary outcome. They demonstrated that TE success rate and ≥ 10 valid measurements had no significant influence on reliability for accurate fibrosis staging. The reliability of LSM was shown to be due to the IQR/M according to the liver stiffness median level, which defined three reliability categories: very reliable (IQR/M ≤ 0.10), reliable (IQR/M between 0.10 and 0.30 or IQR/M > 0.30 with median LSM < 7.1 kPa) and poorly reliable (IQR/M > 0.30 with median LSM ≥ 7.1 kPa).

**CLINICAL APPLICATIONS OF TE IN CURRENT PRACTICE**

*Non-invasive diagnosis of fibrosis and cirrhosis in chronic liver disease*

**CHC:** The primary role of TE is for the non-invasive diagnosis of liver fibrosis with the aim of reducing the need for liver biopsy in the clinical management of chronic liver disease. TE was first developed for and extensively validated in patients with CHC[7,44]. Numerous meta-analyses have demonstrated that TE has a high diagnostic accuracy for the diagnosis of CHC cirrhosis with a mean AUROC of 0.94[45,46]. Castera *et al*[47] established TE as the most accurate non-invasive method for detection of early cirrhosis when compared with other available tests and algorithms. In this study involving 298 CHC patients, the AUROC of TE for detection of cirrhosis was 0.96 compared to 0.82 for Fibrotest®, 0.80 for Lok index and APRI, 0.79 for platelet count, 0.73 for prothrombin index and 0.61 for AST/ALT ratio (*P* < 0.0001). A subsequent larger study of 1839 French patients with CHC confirmed a similar significant superiority of TE over serum markers in excluding cirrhosis[48]. The performance of TE has also been shown to be equally accurate in special populations of CHC patients. These include patients with HCV/HIV co-infection[49,50] and post-transplant HCV[51,52]. The introduction of TE has resulted in a significant reduction in the numbers of liver biopsy in Europe[53].

The recent introduction of highly effective direct antiviral treatment (DAA) for CHC has provided cure rates exceeding 95% with minimal side-effects. With the availability of DAA, all CHC patients should be considered for treatment irrespective of severity of fibrosis since cure is possible. With this paradigm shift in CHC management, the role of non-invasive markers for fibrosis becomes diminished. However, the high cost of such treatment has necessitated prioritization for CHC treatment based on severity of fibrosis. Hence for present day clinicians, TE plays a role to assist in stratifying patients for CHC treatment (Table 2). Based on the latest EASL guidelines, DAA should be prioritized for CHC patients with cirrhosis and advanced fibrosis (F3 and F4), justified in those with significant fibrosis (F2) and individualized in those with no or mild fibrosis (F1 and F0) in whom risk of decompensated cirrhosis and HCC remains low[54].

**CHB:** In the management of patients with CHB, it is most important to distinguish those with inactive disease from those with active hepatitis, as the latter group of patients is more likely to progress to advanced fibrosis and cirrhosis. Even among patients with persistently normal transaminases, a subgroup will present with higher degree of fibrosis and are more likely to have adverse long-term outcomes, particularly those with greater viraemia[55,56]. The main role of TE in CHB is to differentiate patients with significant fibrosis from those with inactive disease without fibrosis. Maimone *et al*[57] demonstrated that the LSM in patients with inactive CHB was significantly lower than those with e-antigen negative CHB. In another study by Fung *et al*[58], TE demonstrated excellent diagnostic accuracy across the entire spectrum of liver fibrosis with good negative predictive value, although caution needs to be exercised when encountering patients with elevated transaminases. Interpretation of LSM is sometimes challenging due to the confounding effect of ALT, but several strategies can be used to circumvent this problem. One is to use different LSM cut-off levels for those with normal and elevated ALT[9] and the other is to use probability-based scores that correct for the ALT level[10]. In routine clinical practice, TE can be used to select patients with higher risk of disease progression and targeted for closer surveillance and consideration of early antiviral therapy.

**NAFLD:**NAFLD is one of the most common chronic liver diseases worldwide, with increasing disease prevalence in parallel with the burgeoning obesity and metabolic syndrome epidemic[59]. NAFLD is a spectrum of disease, ranging in severity from simple steatosis, which is considered relatively benign, to non-alcoholic steatohepatitis (NASH), the more aggressive, severe end of the spectrum. NASH can potentially progress to cirrhosis and accompanying complications such as HCC[60]. Accurate staging of liver fibrosis is important in the management algorithm of NAFLD for aiding treatment decisions and prognostication to monitoring disease progression or treatment response. As such, there have been a myriad of studies exploring the use of TE in patients with NAFLD, with data derived from both Asian and Western series in addition to adult and paediatric cohorts[61-66]. Based on these studies, variable LSM cut-off values for each stage of fibrosis have been reported, with readings of 6.6-7.8, 7.1-10.4 and 10.3-22.3 kPa corresponding to stage F2, F3 and F4, respectively[67]. A recent meta-analysis on the utility of TE in the context of NAFLD included 9 studies consisting of 1047 NAFLD patients[39]. The analysis suggested excellent accuracy in diagnosing F3 or higher (85% sensitivity, 82% specificity) and F4 (92% sensitivity, 92% specificity) while performance was moderate for stage F2 or higher (79% sensitivity, 75% specificity).

**Alcoholic liver disease:** A recent Cochrane Database review examined the diagnostic accuracy of TE for diagnosis and staging of liver fibrosis in patients with alcoholic liver disease[68]. Five retrospective and nine prospective cohort studies with a total of 834 subjects were reviewed. The authors concluded that TE may be used to rule out liver cirrhosis in patients with alcoholic liver disease when the pre-test probability is about 51% (range 15%-79%) using a cut-off value of 12.5 kPa. However the authors cautioned that the optimal cut-off values for assessing fibrosis cannot be established due to the wide range of cut-off values used in individual studies. In a recent study comparing different non-invasive modalities for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease, TE performed better than FibroTest, APRI, Forns and FIB-4 with an optimal LSM of 10.3 kPa for F3 and 18.0 kPa for F4 disease[69,70].

**Cholestatic liver diseases:** TE is a reliable non-invasive means for assessing fibrosis stages in cholestatic liver diseases such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis[71-74]. Optimal stiffness cutoff values of 7.3, 9.8, and 17.3 kPa for F ≥ 2, F ≥ 3 and F ≥ 4 respectively have been proposed[71]. TE has been shown to be significantly superior to biochemical markers such as aspartate aminotransferase (AST)/platelet ratio, FIB-4, hyaluronic acid, AST/alanine aminotransferase ratio, and Mayo score in assessing fibrosis stages in PBC. Furthermore, it has also been shown that serial TE can provide prognostic information, as a 2.1 kPa-per-year increase is associated with an 8.4 fold increased risk of liver decompensations, liver transplantations, or deaths in patients with PBC[72].

**Autoimmune hepatitis:** The utility of TE in autoimmune hepatitis (AIH) is less well validated. There are case reports that described markedly increased liver stiffness in acute AIH. However, liver stiffness normalised after 4 mo of therapy suggesting that liver stiffness measurement can be greatly influenced by florid inflammatory liver process in AIH[75]. Another small case series supported the use of TE in assessing fibrosis in non-viral chronic liver diseases including AIH[73]. Optimal TE cut-off value for AIH has not been established. Therefore, care needs to be taken when performing TE on AIH patients, bearing in mind that uncontrolled inflammation from AIH will increase liver stiffness.

**Post liver transplant:** Several studies have evaluated the role of TE as a non-invasive tool for the detection of hepatic fibrosis due to recurrent hepatitis C following living donor and deceased donor liver transplantation[76-79]. All studies confirmed the excellent correlation of LSM to fibrosis on histology. In addition, Carrion *et al*[76] also showed that TE is an excellent tool to diagnose portal hypertension among patients with advanced fibrosis, cirrhosis and fibrosing cholestatic hepatitis. TE was also shown to be superior to serum markers[77] and other more complex scoring systems for the diagnosis of advanced fibrosis and cirrhosis in this group of liver transplant recipients[78]. These studies suggest that in patients with very low liver stiffness values, liver biopsy may safely be avoided. However, the main drawback of TE is the interpretation of results which correspond to the intermediate stages of fibrosis, where liver biopsy is still mandatory for accurate staging of liver fibrosis[79].

**Other liver diseases:** The availability of reliable non-invasive tools to diagnose liver fibrosis is of tremendous clinical relevance for patients on long-term treatment with methotrexate (MTX) as it helps to avoid routine liver biopsy for assessment of MTX toxicity. Despite a lack of high-quality, prospective studies providing biopsy-paired correlation of the accuracy of TE in this population, the existing literature suggests that TE is an effective non-invasive tool for monitoring MTX toxicity in patients with inflammatory bowel disease, rheumatoid arthritis and psoriasis[80-84]. The prevalence of abnormal LSM values > 7.1 kPa was generally low in this patient population and LSM values are not correlated with the cumulative MTX dose[85]. A recent review from the International Society of Dermatology states that both TE and MRE have outstanding efficacy in detection of liver fibrosis and can help the physician in the decision to use a therapeutic alternative to MTX[86].

In patients with hemochromatosis, an algorithm using serum ferritin levels together with TE was shown to accurately classify the presence of severe fibrosis in 61% of patients, thus avoiding liver biopsy in this group[87]. Together with other studies on patients with hemochromatosis, the evidence suggests a role for TE although more longitudinal prospective studies are required to clearly establish the clinical role of TE in hemochromatosis[88,89].

TE plays a role in the clinical evaluation of individuals with non-cirrhotic portal hypertension[90]. The primary role of TE in this setting is to exclude cirrhosis in patients who present with clinical features suggesting cirrhosis such as splenomegaly, esophageal varices and thrombocytopenia. Compared to cirrhotics, patients with non-cirrhotic portal hypertension have much lower liver stiffness values in the range of 8-9 kPa, which is clearly not compatible with the diagnosis of cirrhosis[91,92].

In summary, TE is the most accurate non-invasive test for the diagnosis of cirrhosis with a high negative predictive value to exclude liver cirrhosis[93]. One important use of TE in clinical practice is to exclude cirrhosis in patients with chronic liver disease, thus avoiding the need for patients to undergo invasive and expensive investigations such as screening gastroscopy for varices and routine HCC surveillance. This translates to a greater cost-effective management for this group of patients. The performance of TE is only moderate for the non-invasive diagnosis of fibrosis and it cannot reliably replace liver biopsy to diagnose milder stages of fibrosis.

*Longitudinal assessment of fibrosis regression*

All the preceding applications of TE were based on a single, point-in-time TE assessment. Intuitively, serial TE measurements should allow one to assess the progression of fibrosis over time or the regression of fibrosis after successful treatment of the underlying liver disease. This has been shown to be possible in chronic viral hepatitis. Vergniol *et al*[94] showed that there was a significant reduction of TE readings in CHC patients successfully treated with pegylated interferon and ribavirin. Regression of fibrosis in CHB patients on antiviral treatment is associated with good outcomes[95-97]. Several short and long-term studies have shown that LSM values consistently decrease over time during continuous antiviral treatment[98-100]. This decrease in liver stiffness is not restricted to patients with milder degree of fibrosis. Kim *et al*[101] reported that a higher liver stiffness value was the only significant factor associated with a decline in liver stiffness value during prolonged antiviral therapy. However, it is known that liver stiffness measurement by TE is increased by elevation of aminotransferases[102]. In a study by Lim *et al*[103], the decrease in liver stiffness value during antiviral therapy was correlated to decrease in liver inflammation on histology but not fibrosis, while contradicting findings were reported by Wong *et al*[104]. Therefore, it remains unclear based on available evidence if a decrease in LSM in treated CHB reflects a regression of liver fibrosis or a decrease in hepatic necroinflammation as a result of viral suppression. In current clinical practice, an emerging role for TE is for the longitudinal monitoring for regression of cirrhosis and fibrosis in patients on antiviral therapy. This role is likely to expand with recent advances in antifibrotic treatment.

*Non-invasive prediction of significant portal hypertension*

In patients with compensated liver cirrhosis, the presence of clinically significant portal hypertension predicts clinical decompensation and poor outcomes[105]. One area of interest in TE is the correlation between LSM and hepatic venous pressure gradient (HVPG). Five studies have evaluated the diagnostic accuracy of TE for diagnosis of clinically significant portal hypertension (defined as HVPG ≥ 10 mmHg)[106-110]. A recent meta-analysis[111] evaluating 18 studies involving 3644 patients with chronic liver disease showed that TE was a good screening tool for detecting significant portal hypertension with 81% probability of correctly detecting significant portal hypertension when the pre-test probability was 50%. Cut-off LSM values ranged from 13.6 to 34.9 kPa with summary sensitivity of 0.90 and 0.79, with PPV of 0.88 and NPV of 0.88. Bureau *et al*[108] reported that a LSM of 21 kPa accurately predicted significant portal hypertension in 92% of patients undergoing paired HVPG and TE with an OR of 120 for HVPG ≥ 10 mmHg. However, Vizzutti *et al*[106] demonstrated that while a strong correlation existed between LSM and HVPG up to a HVPG of 12 mmHg, the correlation was poor at HVPG values beyond 12 mmHg. As such, although there may be a potential role of LSM for screening for presence of significant portal hypertension, it cannot replace HVPG for the quantitative assessment of portal pressures.

*Prediction of liver-related clinical outcomes*

While earlier studies exploring the role of TE in clinical practice focused on cross-sectional studies, there is a wealth of convincing literature which demonstrates that TE has a prognostic role for prediction of important clinical end-points related to progression of fibrosis and cirrhosis[112-114]. In our opinion, this has greater clinical significance compared to point-in-time assessment of cirrhosis. Foucher *et al*[115] were the first to demonstrate that progressively higher LSM values were correlated with clinical decompensation events such as ascites, HCC and variceal bleeding. In this study of 711 CHC patients, various LSM cut-offs had NPV exceeding 90% for different associations, *e.g*., 27.5 kPa for large esophageal varices, 37.5 kPa for Child-Pugh B or C, 49.1 kPa for past history of ascites, 53.7 kPa for HCC and 62.7 kPa for esophageal variceal bleeding.

A significant correlation was shown between TE and presence of esophageal varices[116,117]. In a meta-analysis of 12 studies examining the accuracy of TE for detection of esophageal varices[111], there was a wide range of cut-off LSM values from 15.1 to 28.0 kPa, with a summary sensitivity of 0.87 but poor specificity of 0.53. In a setting of a low pre-test index of suspicion, the probability of a correct diagnosis following a “correct” LSM measurement was less than 70%. Recently Kim *et al*[118] developed a liver stiffness measurement based prediction model which included spleen diameter to platelet ratio, to enable identification of patients with very low likelihood of high risk esophageal varices with a negative predictive value of 94.0%. However, this was a single-centre study where external validation is necessary before the prediction model may be widely used. At present, TE is not sufficiently reliable to replace endoscopy for assessment of esophageal varices in routine clinical practice[119].

Importantly, TE has the potential to predict clinical liver-related events. A prospective study by Robic *et al*[120], demonstrated that a LSM > 21.1 kPa proved as effective as HVPG to predict clinical decompensation and liver-related events (ascites, variceal bleeding, HCC, HE and death). A Japanese study demonstrated in a large 3-year study of 866 CHC patients that a TE value of > 10 kPa carried a significantly higher risk of developing HCC[121]. This finding is not surprising as a TE value of 10 kPa really denotes that a patient has significant fibrosis which is a known association with HCC. Kim *et al*[122] correlated liver stiffness values according to histological sub-classifications of cirrhosis according to Laennec system, and showed that the proportion of liver-related events increased according to the baseline histological sub-classification and LSM prior to starting antiviral therapy. In another study by Lee *et al*[123], TE was shown to be a useful tool to predict liver-related events among CHB patients with complete viral suppression, where patients with LSM > 13.0 kPa had a hazard ratio of 12.0 for any cirrhosis-related decompensation, HCC and liver-related mortality as compared to patients with liver stiffness < 8.0 kPa. These two studies suggest that baseline as well as dynamic change in the liver stiffness value among patients on antiviral therapy can risk stratify patients into those at higher risk of decompensation and mortality, even among those with complete viral suppression. Serial TE in cirrhotic patients may be clinically relevant as increases in serial LSM has been shown to predict clinical outcomes including decompensation, need for liver transplant and death[72].

*Assessment of hepatic steatosis*

The rising prevalence of NAFLD worldwide is becoming an increasing problem in tandem with rising rates of obesity and metabolic syndrome. This raises the need to screen, diagnose and quantify hepatic steatosis in the large population at risk. TE has been shown to be useful for the non-invasive prediction of fibrosis in NAFLD patients and helps to select patients at high risk for progression to cirrhosis and HCC. The introduction and widespread adoption of the XL probe has resolved issues with TE failure in obese NAFLD patients. Apart from fibrosis assessment, the recent introduction of the novel controlled attenuation parameter (CAP) function allows for the non-invasive measurement of hepatic steatosis[124]. CAP measures ultrasound attenuation to quantify hepatic steatosis using the M probe and is expressed in dB/m. Studies have shown that CAP is able to detect more than 5% hepatic steatosis which intuitively is more sensitive than conventional ultrasound which can only detect more than 30% steatosis. In addition, CAP provides comparable accuracy in detection and quantification of hepatic steatosis across a range of liver disease etiologies[125,126]. Further studies are required to explore the robustness and validity of CAP in the study of liver disease. Interestingly, the combination of TE and CAP can simultaneously evaluate hepatic fibrosis and steatosis in a single examination. However, clinicians need to be mindful that this combination of TE and CAP can only predict for fibrosis and steatosis but cannot assess lobular inflammation and balloon degeneration. Hence the reliability of TE to predict clinical progression in NAFLD is limited considering that balloon degeneration is the most important histological feature that predicts disease progression. As such, in contrast to viral hepatitis, TE is unlikely to replace liver biopsy for NAFLD. Currently, the main clinical role for TE in NAFLD is for population screening to detect those with significant steatosis and fibrosis who would benefit from specialty care or treatment. Confirmation of NASH and assessment of severity will still require liver biopsy.

**COMPARISON BETWEEN TE AND OTHER NON-INVASIVE MARKERS OF FIBROSIS**

*TE vs serum markers*

There have been numerous studies comparing the performance of TE against serum markers for the non-invasive diagnosis of liver fibrosis. Overall, the diagnostic accuracy of TE and serum markers are comparable for the diagnosis of significant fibrosis but TE has improved accuracy for the diagnosis of cirrhosis[127]. A large multi-center prospective study comparing TE to serum markers (FIBROSTIC study) of 1307 patients with chronic viral hepatitis concluded that the accuracy of TE was significantly higher than serum markers for predicting cirrhosis. However, all non-invasive markers including TE had only moderate accuracy for predicting significant fibrosis[48]. In another multicentre study, TE was compared against nine serum markers for the diagnosis of fibrosis and cirrhosis in untreated CHC patients. FibroTest, FibroMeter, Hepascore and TE had similar superior performance compared to the other tests[128]. Overall performance of TE was reduced because 22% had uninterpretable results using the M probe. The advantage of serum markers is that it is easily available, inexpensive and does not require specialized equipment and training. However, serum markers can be confounded by biochemical abnormalities (*e.g.*, transaminitis, hemolysis, *etc*.) and do not provide a reflection of the physical degree of fibrosis in the liver. TE provides a more reliable assessment of liver fibrosis but is limited by invalid measurements in obese individuals or those with ascites (Table 3).

*Combining TE and serum markers*

Combination of serum markers with TE can improve the accuracy of fibrosis staging. TE may falsely record high fibrosis scores due to increased stiffness of an inflamed liver. To overcome this weakness, a simple serum marker such as ALT can be used to improve its accuracy. ALT based algorithms for TE measurement of liver fibrosis has been proposed for CHB[9,10]. In addition, it has been demonstrated that spleen diameter and platelet ratio can also be used in combination with TE to improve accuracy[129]. Other markers such as haptoglobin, apolipoprotein A1, and α2-macroglobulin levels have been used in combination with TE to establish a prediction model, called the HALF index, for better estimation of fibrosis staging[130]. Combination of serum markers with TE has been shown to improve the accuracy of detecting fibrosis and cirrhosis[7,128]. The latest clinical practice guidelines from the EASL and AASLD both recommend combination of TE and serum markers as the most efficient method of assessing liver fibrosis in making treatment decisions for patients with CHC[54,131]. Liver biopsy is reserved only in situations where there is discordance between the two non-invasive modalities.

*TE vs MRE*

MRE uses a modified phase-contrast technique to visualise the propagation characteristics of acoustic shear waves generated by an acoustic driver placed over the liver[132]. Early studies have demonstrated that MRE indeed is a feasible alternative method to assess liver elasticity[133-135]. Like TE, MRE has been shown to be repeatable and reproducible[136,137], has been validated against histological fibrosis in various chronic liver diseases including CHB, CHC and NAFLD[138-140] and has been shown to predict esophageal varices[141,142]. MRE is also falsely elevated by necroinflammation[143] but is not affected by steatosis[135].

In a study by Huwart *et al*[144] comparing the performance of TE and MRE in 141 patients with various liver diseases, MRE was shown to be superior to TE in predicting liver fibrosis stage. The better performance of MRE over TE was attributed to several reasons. In MRE, a multi-dimensional displacement vector is assessed as opposed to the 1-dimensional model of TE which improves the shear elastic parameter measured. Also, in MRE, a volume that includes several liver sections is analysed, in contrast to TE which analyses a single cylindrical liver sample of 20-40 mm. Hence, the volume analysed by MRE is far more representative of the liver parenchyma. However, in another study by Bohte *et al*[145], the diagnostic accuracies of TE and MRE for detecting METAVIR F > 2 and F > 3 in patients with CHB and CHC did not differ significantly.

Although there is no conclusive data on superiority of MRE over TE, there are several advantages of MRE over TE. Unlike TE, MRE has a freely oriented field of view without the need for an acoustic window and the latter is one of the important reasons for TE failure. MRE is operator independent and can be used in obese patients and patients with ascites. Perhaps most importantly, MRE can be integrated as part of a comprehensive liver MR imaging examination that can include a conventional diagnostic liver MRI in addition to MRE as well as protocols for assessment of steatosis. The disadvantages of MRE include the high cost, longer examination time, facility constraints and the inability to perform MRE in livers with iron overload due to signal-to-noise limitation. Importantly TE offers the convenience of a rapid bedside procedure which can be done in the clinic and can provide immediate results to the physician.

*TE vs ARFI*

In the last few years, several non-invasive methods have been developed to evaluate liver fibrosis, including TE and ARFI elastography.

ARFI is performed with a Siemens AcusonS2000TM (Siemens AG, Erlangen, Germany) ultrasound system. The ultrasound probe automatically generates shearwaves which propagate into the tissue. The propagation speed increases with fibrosis severity, providing an estimation of the elasticity which is expressed in m/s[146]. Both TE and ARFI have been validated and advocated for assessment of liver fibrosis across a range of liver diseases. In a meta-analysis comparing diagnostic performance of ARFI and TE involving 13 studies and 1163 patients, failure rates were higher in TE compared to ARFI (6.6% *vs* 2.1%); caveat being that the TE evaluations were performed using M probe[146]. In terms of diagnostic accuracy, there were no significant differences between either modality to detect significant fibrosis or cirrhosis. For detection of F2, sensitivity of 0.74 and specificity of 0.83 while sensitivity of 0.78 and specificity of 0.84 was reported for ARFI and TE, respectively. For detection of F4, sensitivity of 0.87 and specificity of 0.87 while sensitivity of 0.89 and specificity of 0.87 was reported for ARFI and TE, respectively.

**CONCLUSION**

The role of TE in clinical practice has evolved over the past decade in tandem with changing trends in clinical management of chronic liver disease. The diagnostic accuracy of TE has been clearly defined for the diagnosis of cirrhosis. In current clinical practice, TE has replaced ultrasound and CT as the most accurate non-invasive method for diagnosis of liver cirrhosis. TE is useful to rule out fibrosis and cirrhosis but does not have sufficient accuracy to discern between various stages of fibrosis. This has led to the recommendation to use TE in combination with serum markers for clinical assessment of fibrosis in CHC. Importantly, the clinical role of TE has evolved from cross-sectional point-in-time assessment of fibrosis and cirrhosis to the more relevant role of prediction of vital clinical end-points. This provides clinicians with the ability to modify treatment strategies based on the information provided by TE. In addition, recent advances in development of antifibrotic therapy will increase the role of serial TE for longitudinal assessment of progression and regression of fibrosis. The availability of the combination of TE and CAP will provide the opportunity to screen at-risk populations with NAFLD for fibrosis and steatosis in a single convenient examination. TE has evolved over the past decade to become an essential tool to assist the clinician in management of chronic liver disease.

**REFERENCES**

1 **D'Amico G**, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006; **44**: 217-231 [PMID: 16298014 DOI: 10.1016/j.hep.2005.10.013]

2 **Ziol M**, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005; **41**: 48-54 [PMID: 15690481 DOI: 10.1002/hep20506]

3 **Shiina T**, Nightingale KR, Palmeri ML, Hall TJ, Bamber JC, Barr RG, Castera L, Choi BI, Chou YH, Cosgrove D, Dietrich CF, Ding H, Amy D, Farrokh A, Ferraioli G, Filice C, Friedrich-Rust M, Nakashima K, Schafer F, Sporea I, Suzuki S, Wilson S, Kudo M. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1: basic principles and terminology. *Ultrasound Med Biol* 2015; **41**: 1126-1147 [PMID: 25805059 DOI: 10.1016/j.ultrasmedbio.2015.03.009]

4 **Sagir A**, Erhardt A, Schmitt M, Häussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. *Hepatology* 2008; **47**: 592-595 [PMID: 18098325 DOI: 10.1002/hep.22056]

5 **Coco B**, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. *J Viral Hepat* 2007; **14**: 360-369 [PMID: 17439526 DOI: 10.1111/j.1365-2893.2006.00811.x]

6 **Arena U**, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, Moscarella S, Boddi V, Petrarca A, Laffi G, Marra F, Pinzani M. Acute viral hepatitis increases liver stiffness values measured by transient elastography. *Hepatology* 2008; **47**: 380-384 [PMID: 18095306 DOI: 10.1002/hep.22007]

7 **Castéra L**, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005; **128**: 343-350 [PMID: 15685546 DOI: 10.1053/j.gastro.2004.11.018]

8 **Marcellin P**, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, Beaugrand M. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. *Liver Int* 2009; **29**: 242-247 [PMID: 18637064 DOI: 10.1111/j.1478-3231.2008.01802.x]

9 **Chan HL**, Wong GL, Choi PC, Chan AW, Chim AM, Yiu KK, Chan FK, Sung JJ, Wong VW. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. *J Viral Hepat* 2009; **16**: 36-44 [PMID: 18673426]

10 **Wong VW**, Lampertico P, de Lédinghen V, Chang PE, Kim SU, Chen Y, Chan HL, Mangia G, Foucher J, Chow WC, Ahn SH, Hou J. Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients. *Dig Dis Sci* 2015; **60**: 1448-1456 [PMID: 25563720 DOI: 10.1007/s10620-014-3488-5]

11 **Berzigotti A**, De Gottardi A, Vukotic R, Siramolpiwat S, Abraldes JG, García-Pagan JC, Bosch J. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. *PLoS One* 2013; **8**: e58742 [PMID: 23520531 DOI: 10.1371/journal.pone.0058742]

12 **Mederacke I**, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, Bahr MJ. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. *Liver Int* 2009; **29**: 1500-1506 [PMID: 19732330 DOI: 10.1111/j.1478-3231.2009.02100.x]

13 **Hopper I**, Kemp W, Porapakkham P, Sata Y, Condon E, Skiba M, Farber L, Porapakkham P, Williams TJ, Menahem S, Roberts S, Krum H. Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography. *Eur J Heart Fail* 2012; **14**: 621-627 [PMID: 22523374 DOI: 10.1093/eurjhf/hfs044]

14 **Millonig G**, Friedrich S, Adolf S, Fonouni H, Golriz M, Mehrabi A, Stiefel P, Pöschl G, Büchler MW, Seitz HK, Mueller S. Liver stiffness is directly influenced by central venous pressure. *J Hepatol* 2010; **52**: 206-210 [PMID: 20022130 DOI: 10.1016/j.jhep.2009.11.018]

15 **Colli A**, Pozzoni P, Berzuini A, Gerosa A, Canovi C, Molteni EE, Barbarini M, Bonino F, Prati D. Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. *Radiology* 2010; **257**: 872-878 [PMID: 20935077 DOI: 10.1148/radiol.10100013]

16 **Jalal Z**, Iriart X, De Lédinghen V, Barnetche T, Hiriart JB, Vergniol J, Foucher J, Thambo JB. Liver stiffness measurements for evaluation of central venous pressure in congenital heart diseases. *Heart* 2015; **101**: 1499-1504 [PMID: 26085526 DOI: 10.1136/heartjnl-2014-307385]

17 **Yoo BW**, Choi JY, Eun LY, Park HK, Park YH, Kim SU. Congestive hepatopathy after Fontan operation and related factors assessed by transient elastography. *J Thorac Cardiovasc Surg* 2014; **148**: 1498-1505 [PMID: 24823284 DOI: 10.1016/j.jtcvs.2014.04.010]

18 **Friedrich-Rust M**, Koch C, Rentzsch A, Sarrazin C, Schwarz P, Herrmann E, Lindinger A, Sarrazin U, Poynard T, Schäfers HJ, Zeuzem S, Abdul-Khaliq H. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers. *J Thorac Cardiovasc Surg* 2008; **135**: 560-567 [PMID: 18329470 DOI: 10.1016/j.jtcvs.2007.09.039]

19 **Wu FM**, Opotowsky AR, Raza R, Harney S, Ukomadu C, Landzberg MJ, Valente AM, Breitbart RE, Singh MN, Gauvreau K, Jonas MM. Transient elastography may identify Fontan patients with unfavorable hemodynamics and advanced hepatic fibrosis. *Congenit Heart Dis* 2014; **9**: 438-447 [PMID: 24418160 DOI: 10.1111/chd.12159]

20 **Trifan A**, Sfarti C, Cojocariu C, Dimache M, Cretu M, Hutanasu C, Stanciu C. Increased liver stiffness in extrahepatic cholestasis caused by choledocholithiasis. *Hepat Mon* 2011; **11**: 372-375 [PMID: 22087164]

21 **Millonig G**, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Büchler MW, Seitz HK, Mueller S. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. *Hepatology* 2008; **48**: 1718-1723 [PMID: 18836992 DOI: 10.1002/hep.22577]

22 **Yashima Y**, Tsujino T, Masuzaki R, Nakai Y, Hirano K, Tateishi R, Sasahira N, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M. Increased liver elasticity in patients with biliary obstruction. *J Gastroenterol* 2011; **46**: 86-91 [PMID: 20814804 DOI: 10.1007/s00535-010-0290-9]

23 **Chang PE**, Lui HF, Chau YP, Lim KH, Yap WM, Tan CK, Chow WC. Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index. *Aliment Pharmacol Ther* 2008; **28**: 51-61 [PMID: 18410556 DOI: 10.1111/j.1365-2036.2008.03711.x]

24 **Fraquelli M**, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut* 2007; **56**: 968-973 [PMID: 17255218]

25 **Castéra L**, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Lédinghen V. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. *Hepatology* 2010; **51**: 828-835 [PMID: 20063276 DOI: 10.1002/hep.23425]

26 **Kettaneh A**, Marcellin P, Douvin C, Poupon R, Ziol M, Beaugrand M, de Lédinghen V. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. *J Hepatol* 2007; **46**: 628-634 [PMID: 17258346]

27 **Lucidarme D**, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, Forzy G, Filoche B, Couzigou P, de Lédinghen V. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. *Hepatology* 2009; **49**: 1083-1089 [PMID: 19140221 DOI: 10.1002/hep.22748]

28 **Ingiliz P**, Chhay KP, Munteanu M, Lebray P, Ngo Y, Roulot D, Benhamou Y, Thabut D, Ratziu V, Poynard T. Applicability and variability of liver stiffness measurements according to probe position. *World J Gastroenterol* 2009; **15**: 3398-3404 [PMID: 19610141]

29 **Pang JX**, Pradhan F, Zimmer S, Niu S, Crotty P, Tracey J, Schneider C, Heitman SJ, Kaplan GG, Swain MG, Myers RP. The feasibility and reliability of transient elastography using Fibroscan®: a practice audit of 2335 examinations. *Can J Gastroenterol Hepatol* 2014; **28**: 143-149 [PMID: 24619636]

30 **Wong GL**, Wong VW, Chim AM, Yiu KK, Chu SH, Li MK, Chan HL. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. *J Gastroenterol Hepatol* 2011; **26**: 300-305 [PMID: 21261720]

31 **de Lédinghen V**, Vergniol J. Transient elastography (FibroScan). *Gastroenterol Clin Biol* 2008; **32**: 58-67 [PMID: 18973847 DOI: 10.1016/S0399-8320(08)73994-0]

32 **de Lédinghen V**, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. *Liver Int* 2010; **30**: 1043-1048 [PMID: 20492500 DOI: 10.1111/j.1478-3231.2010.02258.x]

33 **Şirli R**, Sporea I, Deleanu A, Culcea L, Szilaski M, Popescu A, Dănilă M. Comparison between the M and XL probes for liver fibrosis assessment by transient elastography. *Med Ultrason* 2014; **16**: 119-122 [PMID: 24791843]

34 **Tsochatzis EA**, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. *J Hepatol* 2011; **54**: 650-659 [PMID: 21146892]

35 **Cardoso AC**, Carvalho-Filho RJ, Stern C, Dipumpo A, Giuily N, Ripault MP, Asselah T, Boyer N, Lada O, Castelnau C, Martinot-Peignoux M, Valla DC, Bedossa P, Marcellin P. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. *Liver Int* 2012; **32**: 612-621 [PMID: 22103765 DOI: 10.1111/j.1478-3231.2011.02660.x]

36 **Sporea I**, Sirli R, Deleanu A, Tudora A, Popescu A, Curescu M, Bota S. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: a comparative study. *World J Gastroenterol* 2010; **16**: 4832-4837 [PMID: 20939112]

37 **Yoneda M**, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, Yonemitsu K, Higurashi T, Takahashi H, Kobayashi N, Kirikoshi H, Abe Y, Inamori M, Kubota K, Saito S, Tamano M, Hiraishi H, Maeyama S, Yamaguchi N, Togo S, Nakajima A. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). *Dig Liver Dis* 2008; **40**: 371-378 [PMID: 18083083]

38 **Wong VW**, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, de Lédinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* 2010; **51**: 454-462 [PMID: 20101745]

39 **Kwok R**, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. *Aliment Pharmacol Ther* 2014; **39**: 254-269 [PMID: 24308774 DOI: 10.1111/apt.12569]

40 **Ganne-Carrié N**, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, Dhumeaux D, Trinchet JC, Beaugrand M. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. *Hepatology* 2006; **44**: 1511-1517 [PMID: 17133503]

41 **Viganò M**, Paggi S, Lampertico P, Fraquelli M, Massironi S, Ronchi G, Rigamonti C, Conte D, Colombo M. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. *Aliment Pharmacol Ther* 2011; **34**: 353-362 [PMID: 21631559 DOI: 10.1111/j.1365-2036.2011.04722.x]

42 **Castera L**. Noninvasive methods to assess liver disease in patients with hepatitis B or C. *Gastroenterology* 2012; **142**: 1293-1302.e4 [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017]

43 **Boursier J**, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, Calès P. Determination of reliability criteria for liver stiffness evaluation by transient elastography. *Hepatology* 2013; **57**: 1182-1191 [PMID: 22899556 DOI: 10.1002/hep.25993]

44 **Sandrin L**, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* 2003; **29**: 1705-1713 [PMID: 14698338]

45 **Friedrich-Rust M**, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology* 2008; **134**: 960-974 [PMID: 18395077]

46 **Talwalkar JA**, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2007; **5**: 1214-1220 [PMID: 17916549]

47 **Castéra L**, Le Bail B, Roudot-Thoraval F, Bernard PH, Foucher J, Merrouche W, Couzigou P, de Lédinghen V. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. *J Hepatol* 2009; **50**: 59-68 [PMID: 19013661 DOI: 10.1016/j.jhep.2008.08.018]

48 **Degos F**, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). *J Hepatol* 2010; **53**: 1013-1021 [PMID: 20850886 DOI: 10.1016/j.jhep.2010.05.035]

49 **de Lédinghen V**, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, Dhumeaux D, Beaugrand M. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. *J Acquir Immune Defic Syndr* 2006; **41**: 175-179 [PMID: 16394849]

50 **Vergara S**, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D, Ríos MJ, García-García JA, Camacho A, López-Cortés L, Ruiz J, de la Torre J, Viciana P, Pineda JA. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. *Clin Infect Dis* 2007; **45**: 969-974 [PMID: 17879910]

51 **Rigamonti C**, Donato MF, Fraquelli M, Agnelli F, Ronchi G, Casazza G, Rossi G, Colombo M. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation. *Gut* 2008; **57**: 821-827 [PMID: 18218676 DOI: 10.1136/gut.2007.135046]

52 **Harada N**, Soejima Y, Taketomi A, Yoshizumi T, Ikegami T, Yamashita Y, Itoh S, Kuroda Y, Maehara Y. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. *Transplantation* 2008; **85**: 69-74 [PMID: 18192914 DOI: 10.1097/01.tp.0000297248.18483.16]

53 **Castera L**, Denis J, Babany G, Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? *J Hepatol* 2007; **46**: 528-529; author reply 528-529; [PMID: 17239479]

54 EASL Recommendations on Treatment of Hepatitis C 2015. *J Hepatol* 2015; **63**: 199-236 [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025]

55 **Lin CL**, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, Chen DS, Kao JH. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. *Hepatology* 2007; **45**: 1193-1198 [PMID: 17464993]

56 **Nakazawa T**, Shibuya A, Takeuchi A, Shibata Y, Hidaka H, Okuwaki Y, Takada J, Tanaka Y, Watanabe M, Minamino T, Sakurai K, Koizumi W. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels. *J Viral Hepat* 2011; **18**: e191-e199 [PMID: 21692932 DOI: 10.1111/j.1365-2893.2010.01427.x]

57 **Maimone S**, Calvaruso V, Pleguezuelo M, Squadrito G, Amaddeo G, Jacobs M, Khanna P, Raimondo G, Dusheiko G. An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. *J Viral Hepat* 2009; **16**: 769-774 [PMID: 19709363 DOI: 10.1111/j.1365-2893.2009.01120.x]

58 **Fung J**, Lai CL, Chan SC, But D, Seto WK, Cheng C, Wong DK, Lo CM, Fan ST, Yuen MF. Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. *Am J Gastroenterol* 2010; **105**: 1116-1122 [PMID: 19920809 DOI: 10.1038/ajg.2009.665]

59 **Loomba R**, Sanyal AJ. The global NAFLD epidemic. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 686-690 [PMID: 24042449 DOI: 10.1038/nrgastro.2013.171]

60 **Vernon G**, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011; **34**: 274-285 [PMID: 21623852]

61 **Nobili V**, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. *Hepatology* 2008; **48**: 442-448 [PMID: 18563842 DOI: 10.1002/hep.22376]

62 **Lupsor M**, Badea R, Stefanescu H, Grigorescu M, Serban A, Radu C, Crişan D, Sparchez Z, Iancu S, Maniu A. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. *J Gastrointestin Liver Dis* 2010; **19**: 53-60 [PMID: 20361076]

63 **Petta S**, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. *Aliment Pharmacol Ther* 2011; **33**: 1350-1360 [PMID: 21517924]

64 **Wong VW**, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, Choi PC, Merrouche W, Chu SH, Pesque S, Chan HL, de Lédinghen V. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. *Am J Gastroenterol* 2012; **107**: 1862-1871 [PMID: 23032979 DOI: 10.1038/ajg.2012.331]

65 **Myers RP**, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, Beaton M, Levstik M, Crotty P, Elkashab M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. *Hepatology* 2012; **55**: 199-208 [PMID: 21898479 DOI: 10.1002/hep.24624]

66 **Mahadeva S**, Mahfudz AS, Vijayanathan A, Goh KL, Kulenthran A, Cheah PL. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease. *J Dig Dis* 2013; **14**: 604-610 [PMID: 23859493 DOI: 10.1111/1751-2980.12088]

67 **Yoshioka K**, Hashimoto S, Kawabe N. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. *Hepatol Res* 2015; **45**: 142-151 [PMID: 25040931 DOI: 10.1111/hepr.12388]

68 **Pavlov CS**, Casazza G, Nikolova D, Tsochatzis E, Burroughs AK, Ivashkin VT, Gluud C. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. *Cochrane Database Syst Rev* 2015; **1**: CD010542 [PMID: 25612182]

69 **Fernandez M**, Trépo E, Degré D, Gustot T, Verset L, Demetter P, Devière J, Adler M, Moreno C. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease. *Eur J Gastroenterol Hepatol* 2015; **27**: 1074-1079 [PMID: 26011235 DOI: 10.1097/MEG.0000000000000392]

70 **Mueller S**, Seitz HK, Rausch V. Non-invasive diagnosis of alcoholic liver disease. *World J Gastroenterol* 2014; **20**: 14626-14641 [PMID: 25356026 DOI: 10.3748/wjg.v20.i40.14626]

71 **Corpechot C**, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouillères O, de Lédinghen V, Dhumeaux D, Marcellin P, Beaugrand M, Poupon R. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. *Hepatology* 2006; **43**: 1118-1124 [PMID: 16628644]

72 **Corpechot C**, Carrat F, Poujol-Robert A, Gaouar F, Wendum D, Chazouillères O, Poupon R. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. *Hepatology* 2012; **56**: 198-208 [PMID: 22271046 DOI: 10.1002/hep.25599]

73 **Obara N**, Ueno Y, Fukushima K, Nakagome Y, Kakazu E, Kimura O, Wakui Y, Kido O, Ninomiya M, Kogure T, Inoue J, Kondo Y, Shiina M, Iwasaki T, Yamamoto T, Shimosegawa T. Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. *J Gastroenterol* 2008; **43**: 720-728 [PMID: 18807134 DOI: 10.1007/s00535-008-2225-2]

74 **Friedrich-Rust M**, Müller C, Winckler A, Kriener S, Herrmann E, Holtmeier J, Poynard T, Vogl TJ, Zeuzem S, Hammerstingl R, Sarrazin C. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. *J Clin Gastroenterol* 2010; **44**: 58-65 [PMID: 19581812 DOI: 10.1097/MCG.0b013e3181a84b8d]

75 **Romanque P**, Stickel F, Dufour JF. Disproportionally high results of transient elastography in patients with autoimmune hepatitis. *Liver Int* 2008; **28**: 1177-1178 [PMID: 18783552 DOI: 10.1111/j.1478-3231.2008.01743.x]

76 **Carrión JA**, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. *Liver Transpl* 2006; **12**: 1791-1798 [PMID: 16823833]

77 **Kamphues C**, Lotz K, Röcken C, Berg T, Eurich D, Pratschke J, Neuhaus P, Neumann UP. Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients. *Clin Transplant* 2010; **24**: 652-659 [PMID: 19925459 DOI: 10.1111/j.1399-0012.2009.01152.x]

78 **Beckebaum S**, Iacob S, Klein CG, Dechêne A, Varghese J, Baba HA, Sotiropoulos GC, Paul A, Gerken G, Cicinnati VR. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. *Transplantation* 2010; **89**: 983-993 [PMID: 20335832 DOI: 10.1097/TP.0b013e3181cc66ca]

79 **Adebajo CO**, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. *Liver Transpl* 2012; **18**: 323-331 [PMID: 22140010 DOI: 10.1002/lt.22460]

80 **Laharie D**, Zerbib F, Adhoute X, Boué-Lahorgue X, Foucher J, Castéra L, Rullier A, Bertet J, Couzigou P, Amouretti M, de Lédinghen V. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. *Aliment Pharmacol Ther* 2006; **23**: 1621-1628 [PMID: 16696812]

81 **Park SH**, Choe JY, Kim SK. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. *Joint Bone Spine* 2010; **77**: 588-592 [PMID: 20471892 DOI: 10.1016/j.jbspin.2010.02.024]

82 **Bray AP**, Barnova I, Przemioslo R, Kennedy CT. Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. *Br J Dermatol* 2012; **166**: 1125-1127 [PMID: 21967341 DOI: 10.1111/j.1365-2133.2011.10657.x]

83 **Barbero-Villares A**, Mendoza J, Trapero-Marugan M, Gonzalez-Alvaro I, Daudén E, Gisbert JP, Moreno-Otero R. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. *Med Clin* (Barc) 2011; **137**: 637-639 [PMID: 21719043 DOI: 10.1016/j.medcli.2010.12.024]

84 **Laharie D**, Seneschal J, Schaeverbeke T, Doutre MS, Longy-Boursier M, Pellegrin JL, Chabrun E, Villars S, Zerbib F, de Lédinghen V. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. *J Hepatol* 2010; **53**: 1035-1040 [PMID: 20801541 DOI: 10.1016/j.jhep.2010.04.043]

85 **Lynch M**, Higgins E, McCormick PA, Kirby B, Nolan N, Rogers S, Lally A, Vellinga A, Omar H, Collins P. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. *JAMA Dermatol* 2014; **150**: 856-862 [PMID: 24964792 DOI: 10.1001/jamadermatol.2013.9336]

86 **Kaffenberger BH**, Kaffenberger JA, Wong H, Jarjour W, Levin D, Bechtel MA. Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate? *Int J Dermatol* 2015; **54**: 752-756 [PMID: 26108262 DOI: 10.1111/ijd.12923]

87 **Legros L**, Bardou-Jacquet E, Latournerie M, Guillygomarc'h A, Turlin B, Le Lan C, Désille Y, Lainé F, Moirand R, Brissot P, Deugnier Y, Guyader D. Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis. *Liver Int* 2015; **35**: 1731-1738 [PMID: 25495562 DOI: 10.1111/liv.12762]

88 **Adhoute X**, Foucher J, Laharie D, Terrebonne E, Vergniol J, Castéra L, Lovato B, Chanteloup E, Merrouche W, Couzigou P, de Lédinghen V. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. *Gastroenterol Clin Biol* 2008; **32**: 180-187 [PMID: 18496894]

89 **Castiella A**, Zapata E, Alústiza JM. Non-invasive methods for liver fibrosis prediction in hemochromatosis: One step beyond. *World J Hepatol* 2010; **2**: 251-255 [PMID: 21161006 DOI: 10.4254/wjh.v2.i7.251]

90 **Seijo S**, Reverter E, Miquel R, Berzigotti A, Abraldes JG, Bosch J, García-Pagán JC. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. *Dig Liver Dis* 2012; **44**: 855-860 [PMID: 22721839 DOI: 10.1016/j.dld.2012.05.005]

91 **Chang PE**, Miquel R, Blanco JL, Laguno M, Bruguera M, Abraldes JG, Bosch J, Garcia-Pagan JC. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. *Am J Gastroenterol* 2009; **104**: 1707-1714 [PMID: 19471257 DOI: 10.1038/ajg.2009.165]

92 **Cesari M**, Schiavini M, Marchetti G, Caramma I, Ortu M, Franzetti F, Galli M, Antinori S, Milazzo L. Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature. *AIDS Patient Care STDS* 2010; **24**: 697-703 [PMID: 20969464 DOI: 10.1089/apc.2010.0160]

93 **Barr RG**, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D. Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. *Radiology* 2015; **276**: 845-861 [PMID: 26079489 DOI: 10.1148/radiol.2015150619]

94 **Vergniol J**, Foucher J, Castéra L, Bernard PH, Tournan R, Terrebonne E, Chanteloup E, Merrouche W, Couzigou P, de Lédinghen V. Changes of non-invasive markers and FibroScan values during HCV treatment. *J Viral Hepat* 2009; **16**: 132-140 [PMID: 19175875 DOI: 10.1111/j.1365-2893.2008.01055.x]

95 **Chang TT**, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. *Hepatology* 2010; **52**: 886-893 [PMID: 20683932 DOI: 10.1002/hep.23785]

96 **Dienstag JL**, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. *Gastroenterology* 2003; **124**: 105-117 [PMID: 12512035]

97 **Marcellin P**, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; **381**: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]

98 **Kim SU**, Park JY, Kim do Y, Ahn SH, Choi EH, Seok JY, Lee JM, Park YN, Chon CY, Han KH. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. *Hepatol Int* 2010; **4**: 673-680 [PMID: 21286337 DOI: 10.1007/s12072-010-9201-7]

99 **Enomoto M**, Mori M, Ogawa T, Fujii H, Kobayashi S, Iwai S, Morikawa H, Tamori A, Sakaguchi H, Sawada A, Takeda S, Habu D, Shiomi S, Kawada N. Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. *Hepatol Res* 2010; **40**: 853-861 [PMID: 20887589 DOI: 10.1111/j.1872-034X.2010.00687.x]

100 **Fung J**, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. *J Viral Hepat* 2011; **18**: e200-e205 [PMID: 21692933 DOI: 10.1111/j.1365-2893.2010.01428.x]

101 **Kim MN**, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Han KH. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. *Liver Int* 2014; **34**: 1216-1223 [PMID: 24267737 DOI: 10.1111/liv.12377]

102 **Fung J**, Lai CL, Cheng C, Wu R, Wong DK, Yuen MF. Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B. *Am J Gastroenterol* 2011; **106**: 492-496 [PMID: 21157442 DOI: 10.1038/ajg.2010.463]

103 **Lim SG**, Cho SW, Lee YC, Jeon SJ, Lee MH, Cho YJ, Kim SS, Kim YB, Seok JY, Cheong JY, Kim JH. Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B. *Hepatogastroenterology* 2011; **58**: 539-545 [PMID: 21661428]

104 **Wong GL**, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chu SH, Chan FK, Sung JJ, Chan HL. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. *Antivir Ther* 2011; **16**: 165-172 [PMID: 21447865 DOI: 10.3851/IMP1726]

105 **Ripoll C**, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. *Gastroenterology* 2007; **133**: 481-488 [PMID: 17681169]

106 **Vizzutti F**, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G, Zignego AL, Marra F, Laffi G, Pinzani M. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. *Hepatology* 2007; **45**: 1290-1297 [PMID: 17464971]

107 **Lemoine M**, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F, Grando-Lemaire V, Trinchet JC, Beaugrand M. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. *Aliment Pharmacol Ther* 2008; **28**: 1102-1110 [PMID: 18691352 DOI: 10.1111/j.1365-2036.2008.03825.x]

108 **Bureau C**, Metivier S, Peron JM, Selves J, Robic MA, Gourraud PA, Rouquet O, Dupuis E, Alric L, Vinel JP. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. *Aliment Pharmacol Ther* 2008; **27**: 1261-1268 [PMID: 18397389 DOI: 10.1111/j.1365-2036.2008.03701.x]

109 **Llop E**, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, Abraldes JG, Bruix J, Bosch J, García-Pagan JC. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. *J Hepatol* 2012; **56**: 103-108 [PMID: 21827733 DOI: 10.1016/j.jhep.2011.06.027]

110 **Sánchez-Conde M**, Miralles P, Bellón JM, Rincón D, Ramírez M, Gutiérrez I, Ripoll C, López JC, Cosín J, Clemente G, Lo Iacono O, Bañares R, Berenguer J. Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. *J Viral Hepat* 2011; **18**: 685-691 [PMID: 21914085 DOI: 10.1111/j.1365-2893.2010.01371.x]

111 **Shi KQ**, Fan YC, Pan ZZ, Lin XF, Liu WY, Chen YP, Zheng MH. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. *Liver Int* 2013; **33**: 62-71 [PMID: 22973991 DOI: 10.1111/liv.12003]

112 **Tapper EB**, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. *Clin Gastroenterol Hepatol* 2015; **13**: 27-36 [PMID: 24909907 DOI: 10.1016/j.cgh.2014.04.039]

113 **Singh S**, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, Kamath PS, Talwalkar JA. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 1573-1584.e1-2; quiz e88-89 [PMID: 23954643 DOI: 10.1016/j.cgh.2013.07.034]

114 **Kim BK**, Fung J, Yuen MF, Kim SU. Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. *World J Gastroenterol* 2013; **19**: 1890-1900 [PMID: 23569334 DOI: 10.3748/wjg.v19.i12.1890]

115 **Foucher J**, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Lédinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut* 2006; **55**: 403-408 [PMID: 16020491]

116 **Kazemi F**, Kettaneh A, N'kontchou G, Pinto E, Ganne-Carrie N, Trinchet JC, Beaugrand M. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. *J Hepatol* 2006; **45**: 230-235 [PMID: 16797100]

117 **Pritchett S**, Cardenas A, Manning D, Curry M, Afdhal NH. The optimal cut-off for predicting large oesophageal varices using transient elastography is disease specific. *J Viral Hepat* 2011; **18**: e75-e80 [PMID: 21040236 DOI: 10.1111/j.1365-2893.2010.01375.x]

118 **Kim BK**, Oh HJ, Park JY, Kim do Y, Ahn SH, Han KH, Park Y, Yoo EJ, Park YN, Kim SU. Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. *Liver Int* 2013; **33**: 180-189 [PMID: 23295050 DOI: 10.1111/liv.12020]

119 **Castera L**, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. *J Hepatol* 2012; **56**: 696-703 [PMID: 21767510 DOI: 10.1016/j.jhep.2011.07.005]

120 **Robic MA**, Procopet B, Métivier S, Péron JM, Selves J, Vinel JP, Bureau C. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. *J Hepatol* 2011; **55**: 1017-1024 [PMID: 21354450 DOI: 10.1016/j.jhep.2011.01.051]

121 **Masuzaki R**, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. *Hepatology* 2009; **49**: 1954-1961 [PMID: 19434742 DOI: 10.1002/hep.22870]

122 **Kim BK**, Han KH, Park JY, Ahn SH, Kim JK, Paik YH, Lee KS, Chon CY, Kim do Y. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. *Am J Gastroenterol* 2010; **105**: 1382-1390 [PMID: 20087336 DOI: 10.1038/ajg.2009.750]

123 **Lee HW**, Yoo EJ, Kim BK, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. *Am J Gastroenterol* 2014; **109**: 1241-1249 [PMID: 24957159 DOI: 10.1038/ajg.2014.157]

124 **Sasso M**, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, Poupon R, Cardoso AC, Marcellin P, Douvin C, de Ledinghen V, Trinchet JC, Beaugrand M. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. *J Viral Hepat* 2012; **19**: 244-253 [PMID: 22404722 DOI: 10.1111/j.1365-2893.2011.01534.x]

125 **Kumar M**, Rastogi A, Singh T, Behari C, Gupta E, Garg H, Kumar R, Bhatia V, Sarin SK. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? *J Gastroenterol Hepatol* 2013; **28**: 1194-1201 [PMID: 23425053 DOI: 10.1111/jgh.12134]

126 **Chon YE**, Jung KS, Kim SU, Park JY, Park YN, Kim do Y, Ahn SH, Chon CY, Lee HW, Park Y, Han KH. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. *Liver Int* 2014; **34**: 102-109 [PMID: 24028214 DOI: 10.1111/liv.12282]

127 **Castera L**, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, Asselineau J, Dabis F, Degos F, Salmon D. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. *HIV Med* 2014; **15**: 30-39 [PMID: 24007567 DOI: 10.1111/hiv.12082]

128 **Zarski JP**, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, Bosson JL, Guyader D, Renversez JC, Bronowicki JP, Gelineau MC, Tran A, Trocme C, De Ledinghen V, Lasnier E, Poujol-Robert A, Ziegler F, Bourliere M, Voitot H, Larrey D, Rosenthal-Allieri MA, Fouchard Hubert I, Bailly F, Vaubourdolle M. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. *J Hepatol* 2012; **56**: 55-62 [PMID: 21781944 DOI: 10.1016/j.jhep.2011.05.024]

129 **Kim BK**, Han KH, Park JY, Ahn SH, Chon CY, Kim JK, Paik YH, Lee KS, Park YN, Kim do Y. A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. *Liver Int* 2010; **30**: 1073-1081 [PMID: 20492510 DOI: 10.1111/j.1478-3231.2010.02269.x]

130 **Lee HJ**, Seo YS, Kim DJ, Kang HS, An H, Kim JH, Cheong JY, Yim HJ, Yeon JE, Lee HS, Byun KS, Cho SW, Kim DJ, Um SH, Kim CD, Ryu HS. Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B. *J Gastroenterol Hepatol* 2011; **26**: 987-995 [PMID: 21198828 DOI: 10.1111/j.1440-1746.2010.06609.x]

131 **AASLD/IDSA HCV Guidance Panel**. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology* 2015; **62**: 932-954 [PMID: 26111063 DOI: 10.1002/hep.27950]

132 **Muthupillai R**, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehman RL. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. *Science* 1995; **269**: 1854-1857 [PMID: 7569924]

133 **Huwart L**, Peeters F, Sinkus R, Annet L, Salameh N, ter Beek LC, Horsmans Y, Van Beers BE. Liver fibrosis: non-invasive assessment with MR elastography. *NMR Biomed* 2006; **19**: 173-179 [PMID: 16521091]

134 **Huwart L**, Sempoux C, Salameh N, Jamart J, Annet L, Sinkus R, Peeters F, ter Beek LC, Horsmans Y, Van Beers BE. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. *Radiology* 2007; **245**: 458-466 [PMID: 17940304]

135 **Yin M**, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, Fidler JL, Ehman RL. Assessment of hepatic fibrosis with magnetic resonance elastography. *Clin Gastroenterol Hepatol* 2007; **5**: 1207-1213.e2 [PMID: 17916548]

136 **Lee Yj**, Lee JM, Lee JE, Lee KB, Lee ES, Yoon JH, Yu MH, Baek JH, Shin CI, Han JK, Choi BI. MR elastography for noninvasive assessment of hepatic fibrosis: reproducibility of the examination and reproducibility and repeatability of the liver stiffness value measurement. *J Magn Reson Imaging* 2014; **39**: 326-331 [PMID: 23589232 DOI: 10.1002/jmri.24147]

137 **Runge JH**, Bohte AE, Verheij J, Terpstra V, Nederveen AJ, van Nieuwkerk KM, de Knegt RJ, Baak BC, Jansen PL, Sinkus R, Stoker J. Comparison of interobserver agreement of magnetic resonance elastography with histopathological staging of liver fibrosis. *Abdom Imaging* 2014; **39**: 283-290 [PMID: 24366108 DOI: 10.1007/s00261-013-0063-z]

138 **Venkatesh SK**, Wang G, Lim SG, Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. *Eur Radiol* 2014; **24**: 70-78 [PMID: 23928932 DOI: 10.1007/s00330-013-2978-8]

139 **Shire NJ**, Yin M, Chen J, Railkar RA, Fox-Bosetti S, Johnson SM, Beals CR, Dardzinski BJ, Sanderson SO, Talwalkar JA, Ehman RL. Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. *J Magn Reson Imaging* 2011; **34**: 947-955 [PMID: 21751289 DOI: 10.1002/jmri.22716]

140 **Loomba R**, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, Valasek M, Lin G, Brenner D, Gamst A, Ehman R, Sirlin C. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. *Hepatology* 2014; **60**: 1920-1928 [PMID: 25103310 DOI: 10.1002/hep.27362]

141 **Shin SU**, Lee JM, Yu MH, Yoon JH, Han JK, Choi BI, Glaser KJ, Ehman RL. Prediction of esophageal varices in patients with cirrhosis: usefulness of three-dimensional MR elastography with echo-planar imaging technique. *Radiology* 2014; **272**: 143-153 [PMID: 24620910 DOI: 10.1148/radiol.14130916]

142 **Sun HY**, Lee JM, Han JK, Choi BI. Usefulness of MR elastography for predicting esophageal varices in cirrhotic patients. *J Magn Reson Imaging* 2014; **39**: 559-566 [PMID: 24115368 DOI: 10.1002/jmri.24186]

143 **Shi Y**, Guo Q, Xia F, Dzyubak B, Glaser KJ, Li Q, Li J, Ehman RL. MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: does histologic necroinflammation influence the measurement of hepatic stiffness? *Radiology* 2014; **273**: 88-98 [PMID: 24893048 DOI: 10.1148/radiol.14132592]

144 **Huwart L**, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, Peeters F, ter Beek LC, Rahier J, Sinkus R, Horsmans Y, Van Beers BE. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. *Gastroenterology* 2008; **135**: 32-40 [PMID: 18471441 DOI: 10.1053/j.gastro.2008.03.076]

145 **Bohte AE**, de Niet A, Jansen L, Bipat S, Nederveen AJ, Verheij J, Terpstra V, Sinkus R, van Nieuwkerk KM, de Knegt RJ, Baak BC, Jansen PL, Reesink HW, Stoker J. Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. *Eur Radiol* 2014; **24**: 638-648 [PMID: 24158528 DOI: 10.1007/s00330-013-3046-0]

146 **Bota S**, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, Peck-Radosavljevic M. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. *Liver Int* 2013; **33**: 1138-1147 [PMID: 23859217 DOI: 10.1111/liv.12240]

**P-Reviewer:** Cosgrove DO, Sirli R,Sporea I **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Optimal cut-off values for liver stiffness measurement in different etiologies of chronic liver disease**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Optimal cut-off LSM for F2** | **Optimal cut-off LSM for F3** | **Optimal cut-off for LSM F4** | **Ref.** |
| Chronic hepatitis C | 7.6 (5.1-10.1) | 10.9 (8.0-15.4) | 15.3 (11.9-26.5) | [33] |
| Chronic hepatitis B | 7.0 (6.9-7.2) | 8.2 (7.3-9.0) | 11.3 (9.0-13.4) | [33] |
| Alcoholic liver disease | 8.9 (2.8-46.4) | 10.3 (7.7-20.8) | 18.4 (12.2-75.0) | [66] |
| Non-alcoholic fatty liver disease | 7.0 (6.7-7.8) | 8.7 (7.1-10.4) | 10.3 (10.3-22.3) | [35-37] |
| Cholestatic liver disease | 7.3 | 9.8 | 17.3 | 54 |

LSM: Liver stiffness measurement.

**Table 2 What the clinician needs to know about transient elastography (Fibroscan®)**

|  |
| --- |
| **1 Clinical indications for TE** |
| **Liver disease** | **Indications for TE** | **Potential clinical applications** |
| Chronic liver disease  | To assess for severity of fibrosis  | Assist in treatment decisions in CHC and CHBSelection of patients for treatment trialsDecision to continue or stop MTX  |
| To diagnose early cirrhosis  | Commence variceal screening and HCC surveillance, monitor for decompensation  |
| Longitudinal assessment of fibrosis | Assess for progression of fibrosis in untreated patients and for regression of fibrosis/cirrhosis in treated patients |
| Patients with NAFLD | Assess severity of fibrosis and steatosis (with Fibroscan-CAP) | Aggressive control of risk factorsSelection of patients for treatment trialsSelection of patients for liver biopsy |
| Post-liver transplant | Assess for fibrosis in recurrent CHC post liver transplant | Avoid protocol liver biopsies for diagnosis of fibrosis  |
| Non-cirrhotic portal hypertension | Exclude cirrhosis | Assists in differentiating cirrhotic *vs* non-cirrhotic portal hypertension |
| Patients with cirrhosis | Predict significant portal hypertension and risk of liver-related events | Stratify frequency of follow-up in low-risk *vs* high-risk cirrhotics |
| Predict absence of varices | Avoid/delay endoscopy screening in cirrhotics at low risk for varices |
| **2 Conditions that affect accuracy of TE** |
| **Condition** | **How it affects the TE result** | **What the clinician should do** |
| Post-meal | LSMs are elevated after meals due to increased hepatic venous flow | Patients should fast for at least 3 h before TE measurement |
| Elevated ALT | LSMs are elevated due to hepatic inflammation | Repeat or delay TE till after ALT has returned to baseline/normal levelsUse ALT-based LSM cut-off values to interpret LSM resultUse probability-based LSM interpretation scores which account for ALT |
| Cardiac failure | LSMs are elevated due to hepatic congestion in right heart failure | Repeat or delay TE until after patient’s heart failure is treated |
| Cholestasis | LSMs are elevated due to increased stiffness from biliary dilatation  | Repeat or delay TE until after biliary obstruction is resolved |
| Operator experience | Operator inexperience may lead to higher rate of unsuccessful or invalid LSM results | TE should be performed by operators with prior experience of at least 50-100 examinations |
| Obesity | Higher rate of unsuccessful LSMs due to increased SCD because of increased subcutaneous fat  | Use XL probe if SCD > 3.4 cm (with the current Fibroscan 502 Touch®, the machine will automatically advise when the XL probe should be used)If LSM is unsuccessful with XL probe, use alternative non-invasive test  |
| Ascites  | High rate of unsuccessful LSM due to interruption of shear waves by ascites | Use alternative non-invasive test |
| Pregnancy, cardiac pacemaker, AICD | Safety of TE in these conditions have not been assessed | TE contraindicated |

TE: Transient elastography; CHC: Chronic hepatitis C; CHB: Chronic hepatitis B; MTX: Methotrexate; HCC: Hepatocellular carcinoma; CAP: Controlled attenuation parameter; NAFLD: Non-alcoholic fatty liver disease; LSM: Liver stiffness measurement; ALT: Alanine transaminase; SCD: Skin-capsule distance.

**Table 3 Comparison of non-invasive modalities for assessment of fibrosis**

|  |  |  |
| --- | --- | --- |
| **Non-invasive test** | **Advantages** | **Disadvantages** |
| Transient elastography | Easy to performPainless and comfortableCan be done in clinic or officeProvides immediate results for clinicianWell-validatedCan be performed reliably in obese patients with the use of XL probeReadily available in most centres | Requires costly equipmentUnreliable in patients with severe obesity and ascitesRequires technical expertise Requires fastingInterpretation of LSM result dependent on etiology, ALT, *etc.*Only assesses part of the liver |
| Serum markers  | Easy to performInexpensiveDoes not require training or equipmentWell-validatedEasily repeatable | Results can be confounded by biochemical abnormalitiesIndirect reflection of liver fibrosisDoes not assess liver stiffness directlySome tests are proprietary and are relatively costly |
| MRE | Multi-dimensional assessment Able to assess whole liverOperator independenceCan be performed in obese patients and those with ascitesCan be integrated as part of a comprehensive MRI examination | High costLimited availabilityCannot be performed in subjects with claustrophobiaLong examination timeCannot be performed in livers with iron overload |
| ARFI/SWE | Higher success rate compared to TE (using M probe)Similar accuracy to TECan be performed in obese patients and those with ascitesCan assess whole liverCan assess specific part of the liver (*i.e*., region of interest) | Requires special equipment and technical expertiseOperator-dependentNot widely available  |

TE: Transient elastography; MRE: Magnetic resonance elastography; ARFI: Acoustic radiation force impulse; SWE: Shear wave elastography.